Jane Zveiter de Moraes

• Abstract

  Immunotherapy has become an important topic of many cancer treatment protocols. It is known that tumor cells secrete factors critically involved in the formation and maintenance of angiogenesis. Among the most expressed, it is the vascular endothelial growth factor (VEGF). Bevacizumab is the first and most promising humanized anti-VEGF monoclonal antibody (mAb) approved for the treatment …

  Evaluation of the effects of VEGF-binding anti-anti-bevacizumab idiotype antibodies on the expression of angiogenic mediators in human tumor and endothelial cell lines, AP.R

• Abstract

  The immunotherapy has been considered important therapeutic tool in the treatment of malignancies. The antiangiogenic strategy is among the most promising approaches. The vascular endothelial growth factor (VEGF) plays a critical role in the angiogenic process mainly in solid tumors. Bevacizumab is an anti-VEGF humanized monoclonal antibody, which has been used in treating a variety of tu…

  Study of the effect of anti-Id antibody 10.D7 in inhibiting metastasis and construction of genetic vaccine, scFv 10.D7, which mimics growth factor vascular endothelium (VEGF), AP.R

• Abstract

  Tumors require blood supply and, to overcome this restriction, induce angiogenesis. The vascular endothelial growth factor (VEGF) is an important player in this process, which explains the great number of antiangiogenic therapies targeting it. Its relevance culminated with the approval of bevacizumab, a humanized anti-VEGF monoclonal antibody (mAb), in clinical settings. However, side eff…

  Anti-bevacizumab idiotype antibody vaccination is effective in inducing VEGF-binding response, impairing tumor outgrowth, PUB.ART

(Only some records are available in English at this moment)

• Abstract

  Cancer corresponds to a set of diseases that have in common the disordered growth of cells, and have the capacity to invade neighboring and distant tissues and organs. Immunotherapy focused on the angiogenesis process may be an alternative to inhibit tumor growth. Based on this idea, our group successfully developed monoclonal antibodies (mAbs) that interfere with murine model tumor growt…

  Obtainment of anti-idiotypic (ID) monoclonal antibodies (mAb) capable to mimicry hFGF2, BP.IC

• Abstract

  Melanoma is the leading fatal disease originating from the skin. Serious adverse effects of conventional therapies make the seeking of new options of treatment necessary. Immunotherapies represent an alternative and, among them, the anti-angiogenic approaches are promising. The vascular endothelial growth factor (VEGF) plays a critical role in the angiogenic process. Bevacizumab is a huma…

  Evaluation of the inhibition potential of the anti-Id mAb 10.D7, which mimics endothelial growth factor (VEGF), on the growth of B16F10 melanoma, BP.IC

• Abstract

  Melanoma is the leading fatal illness arising from the skin. Currently, the conventional therapeutic modalities used for melanoma have not improved the survival of patients. Given that, immune therapies are being increasingly investigated. Studies on the molecular level show that changes in the expression pattern of gangliosides on the cell surface occur during the process of malignant tr…

  Identification of the epitope recognized by anti-anti-Id mAb 5.G8, BP.IC

(Only some records are available in English at this moment)